Phaseline

Targets › CD14

CD14 (Monocyte differentiation antigen CD14): drug programs, companies and trials

1 program from 1 company in 3 trials: 2 Phase 1, 1 Phase 2; Cardiovascular, Respiratory; next expected readout Mar 2029.

Coreceptor for bacterial lipopolysaccharide. In concert with LBP, binds to monomeric lipopolysaccharide and delivers it to the LY96/TLR4 complex, thereby mediating the innate immune response to bacterial lipopolysaccharide (LPS). (UniProt, P08571)

Open in Phaseline: the race on CD14, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Implicit BioscienceIc14 (IC14)
Monocyte differentiation antigen CD14 inhibitor
CD14Phase 2Acute Respiratory Distress Syndrome; Acute Decompensated Heart Failure; STEMIMar 2029

Conditions

Acute Respiratory Distress Syndrome (1) Acute Decompensated Heart Failure (1) STEMI (1)

Modalities

antibody (1)

Companies

Implicit Bioscience (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.